YD Bio (YDES) Common Equity (2024 - 2025)
YD Bio's (YDES) quarterly Common Equity came in at -$2855.7 billion in Q4 2025, down 143.33% year-on-year from $6590.2 billion in Q4 2024, and down 56123886.42% on a QoQ basis from $5.1 million in Q2 2025.
YD Bio (YDES) Common Equity (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Common Equity data on file, last reported at -$2855.7 billion in Q4 2025.
- On a quarterly basis, Common Equity fell 143.33% year-over-year to -$2855.7 billion in Q4 2025; TTM through Dec 2025 was -$2855.7 billion, a 143.33% decrease from a year earlier, with the FY2025 full-year figure at -$2855.7 billion, down 143.33% from the prior year.
- Common Equity for Q4 2025 stood at -$2855.7 billion, down from $5.1 million in the prior quarter.
- Over the last five years, Common Equity for YDES reached as high as $6590.2 billion in Q4 2024 and fell as low as -$2855.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -98.34 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 14.38 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.76 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 1.50 Bn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | -2,855.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,855.66 Bn |
| Jun 30, 2025 | 5.09 Mn |
| Dec 31, 2024 | 6,590.25 Bn |